Genotonorm (Somatropin)

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Fetal Growth Retardation

Conditions

Fetal Growth Retardation

Trial Timeline

Feb 1, 2005 → Apr 1, 2009

NCT ID

NCT00174252

About Genotonorm (Somatropin)

Genotonorm (Somatropin) is a phase 3 stage product being developed by Pfizer for Fetal Growth Retardation. The current trial status is completed. This product is registered under clinical trial identifier NCT00174252. Target conditions include Fetal Growth Retardation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00174252	Phase 3	Completed	Feb 1, 2005	Apr 1, 2009	Fetal Growth Retardation

Competing Products

3 competing products in Fetal Growth Retardation

See all competitors

Product	Company	Stage	Hype Score
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	44
Strattera + Placebo	Eli Lilly	Phase 1	33
somatropin + somatropin	Sanofi	Phase 3	76

Other Products from Pfizer